Literature DB >> 32777076

Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?

Tejpal Gupta1,2, Abhishek Chatterjee1,2, Vijay Patil3.   

Abstract

Entities:  

Keywords:  adjuvant; extended; glioblastoma; survival; temozolomide

Mesh：

Substances：

Year:  2020        PMID： 32777076      PMCID： PMC7746932          DOI： 10.1093/neuonc/noaa194

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

2.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

3.  Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Authors:  Ulrich Herrlinger; Theophilos Tzaridis; Frederic Mack; Joachim Peter Steinbach; Uwe Schlegel; Michael Sabel; Peter Hau; Rolf-Dieter Kortmann; Dietmar Krex; Oliver Grauer; Roland Goldbrunner; Oliver Schnell; Oliver Bähr; Martin Uhl; Clemens Seidel; Ghazaleh Tabatabai; Thomas Kowalski; Florian Ringel; Friederike Schmidt-Graf; Bogdana Suchorska; Stefanie Brehmer; Astrid Weyerbrock; Miriam Renovanz; Lars Bullinger; Norbert Galldiks; Peter Vajkoczy; Martin Misch; Hartmut Vatter; Moritz Stuplich; Niklas Schäfer; Sied Kebir; Johannes Weller; Christina Schaub; Walter Stummer; Jörg-Christian Tonn; Matthias Simon; Vera C Keil; Michael Nelles; Horst Urbach; Martin Coenen; Wolfgang Wick; Michael Weller; Rolf Fimmers; Matthias Schmid; Elke Hattingen; Torsten Pietsch; Christoph Coch; Martin Glas
Journal:  Lancet       Date:  2019-02-14       Impact factor: 79.321

4.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Authors:  Carmen Balana; Maria Angeles Vaz; Juan Manuel Sepúlveda; Carlos Mesia; Sonia Del Barco; Estela Pineda; Jose Muñoz-Langa; Anna Estival; Ramón de Las Peñas; Jose Fuster; Regina Gironés; Luis Miguel Navarro; Miguel Gil-Gil; Miriam Alonso; Ana Herrero; Sergio Peralta; Clara Olier; Pedro Perez-Segura; Maria Covela; Maria Martinez-García; Alfonso Berrocal; Oscar Gallego; Raquel Luque; Franciso Javier Perez-Martín; Anna Esteve; Nuria Munne; Marta Domenech; Salvador Villa; Carolina Sanz; Cristina Carrato
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

5.  Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Authors:  Deborah T Blumenthal; Thierry Gorlia; Mark R Gilbert; Michelle M Kim; L Burt Nabors; Warren P Mason; Monika E Hegi; Peixin Zhang; Vassilis Golfinopoulos; James R Perry; Do Hyun Nam; Sara C Erridge; Benjamin W Corn; René O Mirimanoff; Paul D Brown; Brigitta G Baumert; Minesh P Mehta; Martin J van den Bent; David A Reardon; Michael Weller; Roger Stupp
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

6.  The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review.

Authors:  Ehsan Alimohammadi; Seyed Reza Bagheri; Shahram Taheri; Maliheh Dayani; Alireza Abdi
Journal:  Oncol Rev       Date:  2020-02-18
  6 in total
  1 in total

Review 1.  Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis.

Authors:  Tejpal Gupta; Riddhijyoti Talukdar; Sadhana Kannan; Archya Dasgupta; Abhishek Chatterjee; Vijay Patil
Journal:  Neurooncol Pract       Date:  2022-05-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.